Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Ultragenyx Lawsuit - RARE
09:00am, Wednesday, 01'st Apr 2026
NEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsuit.
PHILADELPHIA, April 01, 2026 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: R
NEW YORK and NEW ORLEANS, March 31, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultra
New York, New York--(Newsfile Corp. - March 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) bet
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ:
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND
01:16pm, Tuesday, 31'st Mar 2026
RARE's IND for UX016, a novel sialic acid prodrug targeting GNEM, a rare muscle disease, gets accepted by the FDA. The first-in-human study is slated for H2'26.
RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026
09:19am, Tuesday, 31'st Mar 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acqui
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors
09:00am, Tuesday, 31'st Mar 2026
LOS ANGELES, March 31, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ultragenyx Pharmaceutical, Inc., (“Ultragenyx” or the "Company") (NASDAQ: RARE) investors of a class action on behalf
NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE duri
NEW YORK, March 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., March 30, 2026. Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc
Philadelphia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:20am, Monday, 30'th Mar 2026
LOS ANGELES, March 30, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc.
Program to be externally funded by a venture philanthropy agreement through clinical proof-of-concept, including the Phase 1/2 study planned to begin in the second half of 2026 Program to be externall
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
03:41am, Monday, 30'th Mar 2026
LOS ANGELES, March 30, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for vio
